

# Sabina Signoretti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4789648/publications.pdf>

Version: 2024-02-01

258  
papers

32,226  
citations

4955

84  
h-index

4427

172  
g-index

265  
all docs

265  
docs citations

265  
times ranked

41652  
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrative clinical and molecular characterization of translocation renal cell carcinoma. <i>Cell Reports</i> , 2022, 38, 110190.	2.9	40
2	Blocking PI3K p110 $\beta$ Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 673-685.	1.5	6
3	Anti-CAIX BB $\gamma$ CAR4/8 T $\alpha$ cells exhibit superior efficacy in a ccRCC mouse model. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 385-399.	2.0	15
4	Initial results of a phase II study of nivolumab(N) and ipilimumab(I) in genitourinary malignancies with neuroendocrine differentiation.. <i>Journal of Clinical Oncology</i> , 2022, 40, 569-569.	0.8	0
5	Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up.. <i>Journal of Clinical Oncology</i> , 2022, 40, 352-352.	0.8	8
6	Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. <i>JCO Precision Oncology</i> , 2022, 6, e2100448.	1.5	5
7	Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced clear cell renal cell (HCRN GU16-260-Cohort A): Final report.. <i>Journal of Clinical Oncology</i> , 2022, 40, 288-288.	0.8	6
8	Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2120403119.	3.3	11
9	Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung Cancer. <i>Cancer Research</i> , 2022, 82, 248-263.	0.4	17
10	Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial. <i>Clinical Cancer Research</i> , 2022, 28, 748-755.	3.2	9
11	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. <i>Clinical Cancer Research</i> , 2022, 28, 831-839.	3.2	12
12	Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). <i>Journal of Clinical Oncology</i> , 2022, 40, 2913-2923.	0.8	40
13	Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3633-3641.	0.8	12
14	Molecular characterization of the tumor microenvironment in chromophobe renal cell carcinoma (ChRCC) and related oncocytic neoplasms.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4549-4549.	0.8	0
15	Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC): The JAVELIN Renal 101 experience.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4531-4531.	0.8	3
16	Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 4045-4055.	3.2	12
17	KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. <i>Cancer Immunology Research</i> , 2021, 9, 156-169.	1.6	56
18	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1371-1380.	3.2	49

#	ARTICLE	IF	CITATIONS
19	Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 78-86.	3.2	154
20	ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	29
21	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. <i>Nature Communications</i> , 2021, 12, 808.	5.8	84
22	Development of a Histopathology Informatics Pipeline for Classification and Prediction of Clinical Outcomes in Subtypes of Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 2868-2878.	3.2	32
23	PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4596-TPS4596.	0.8	5
24	Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 649-661.e5.	7.7	263
25	Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 632-648.e8.	7.7	230
26	A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes. <i>Clinical Cancer Research</i> , 2021, 27, 4836-4847.	3.2	20
27	Abstract 62: Development of dual-targeted fine-tuned immune restoring (DFIR) CAR T cell therapy for clear cell renal cell carcinoma (ccRCC). <i>Cancer Research</i> , 2021, 81, 62-62.	0.4	2
28	Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. <i>BMC Cancer</i> , 2021, 21, 904.	1.1	10
29	<i>BRCA1/Trp53</i> heterozygosity and replication stress drive esophageal cancer development in a mouse model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	5
30	Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 690-696.	1.9	11
31	Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. <i>Journal of Clinical Oncology</i> , 2020, 38, 63-70.	0.8	109
32	A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. <i>British Journal of Cancer</i> , 2020, 122, 555-563.	2.9	59
33	Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma. , 2020, 8, e001467.		22
34	Efficacy of Savolitinib vs Sunitinib in Patients With <i>MET</i> -Driven Papillary Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2020, 6, 1247.	3.4	105
35	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. <i>Nature Medicine</i> , 2020, 26, 909-918.	15.2	488
36	Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. <i>Cancer Immunology Research</i> , 2020, 8, 1075-1084.	1.6	47

#	ARTICLE	IF	CITATIONS
37	SAVOIR: A phase III study of savolitinib versus sunitinib in pts with MET-driven papillary renal cell carcinoma (PRCC).. Journal of Clinical Oncology, 2020, 38, 5002-5002.	0.8	5
38	Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260).. Journal of Clinical Oncology, 2020, 38, 5006-5006.	0.8	48
39	Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade.. Journal of Clinical Oncology, 2020, 38, 5010-5010.	0.8	2
40	Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial.. Journal of Clinical Oncology, 2020, 38, 5023-5023.	0.8	6
41	Association of gene expression with clinical outcomes in patients with renal cell carcinoma treated with pembrolizumab in KEYNOTE-427.. Journal of Clinical Oncology, 2020, 38, 5024-5024.	0.8	9
42	MET status and treatment outcomes in papillary renal cell carcinoma (PRCC): Pooled analysis of historical data.. Journal of Clinical Oncology, 2020, 38, e19321-e19321.	0.8	4
43	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma (S/R RCC) to reveal potential determinants of poor prognosis and response to immune checkpoint inhibitors (ICI).. Journal of Clinical Oncology, 2020, 38, 715-715.	0.8	3
44	PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).. Journal of Clinical Oncology, 2020, 38, TPS765-TPS765.	0.8	1
45	PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).. Journal of Clinical Oncology, 2020, 38, TPS5101-TPS5101.	0.8	3
46	Evaluation of RNA-sequencing (RNA-seq) signatures with pembrolizumab (pembro) in patients (pts) with renal cell carcinoma (RCC) from KEYNOTE-427 cohort A.. Journal of Clinical Oncology, 2020, 38, 729-729.	0.8	0
47	Circulating immune cell populations and cytokines in patients with metastatic variant histology renal cell carcinoma (vRCC) treated with atezolizumab plus bevacizumab (AB): Dynamic changes on therapy and association with outcomes from a phase II trial.. Journal of Clinical Oncology, 2020, 38, 740-740.	0.8	1
48	The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?. Future Oncology, 2019, 15, 1683-1695.	1.1	35
49	Editor's Note: The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma. Clinical Cancer Research, 2019, 25, 4194-4194.	3.2	0
50	The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis. Genes and Development, 2019, 33, 1718-1738.	2.7	65
51	PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. Clinical Cancer Research, 2019, 25, 6080-6088.	3.2	50
52	Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nature Communications, 2019, 10, 4346.	5.8	139
53	HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species. Science Signaling, 2019, 12, .	1.6	47
54	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clinical Cancer Research, 2019, 25, 2174-2184.	3.2	80

#	ARTICLE	IF	CITATIONS
55	Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate. <i>Science</i> , 2019, 363, 1217-1222.	6.0	281
56	A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. <i>Nature Communications</i> , 2019, 10, 1617.	5.8	499
57	Cells Lacking the <i>Rb1</i> Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival. <i>Cancer Discovery</i> , 2019, 9, 230-247.	7.7	119
58	Association of polybromo-associated BAF (PBAF) complex mutations with overall survival (OS) in cancer patients (pts) treated with checkpoint inhibitors (ICIs).. <i>Journal of Clinical Oncology</i> , 2019, 37, 103-103.	0.8	5
59	Efficacy of immune checkpoint inhibitors (ICI) and genomic characterization of sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4514-4514.	0.8	5
60	Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4568-4568.	0.8	4
61	Atezolizumab plus bevacizumab in non-clear cell renal cell carcinoma (NccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (ccRCCsd): Updated results of activity and predictive biomarkers from a phase II study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4583-4583.	0.8	11
62	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS4597-TPS4597.	0.8	3
63	Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 548-548.	0.8	21
64	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS684-TPS684.	0.8	11
65	Prognostic significance of CD73 expression in localized renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4582-4582.	0.8	0
66	Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 118, 1238-1242.	2.9	33
67	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. <i>Cell Reports</i> , 2018, 23, 313-326.e5.	2.9	523
68	An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. <i>Nature Genetics</i> , 2018, 50, 206-218.	9.4	229
69	Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms. <i>Nature Medicine</i> , 2018, 24, 165-175.	15.2	137
70	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. <i>Science</i> , 2018, 359, 801-806.	6.0	898
71	Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E3741-E3748.	3.3	10
72	Metastatic penile carcinoma associated with convergent gain-of-function mutations in NOTCH1. <i>Human Pathology: Case Reports</i> , 2018, 11, 19-20.	0.2	1

#	ARTICLE	IF	CITATIONS
73	Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. <i>Journal of Clinical Oncology</i> , 2018, 36, 3553-3559.	0.8	49
74	Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. <i>PLoS Genetics</i> , 2018, 14, e1007679.	1.5	14
75	Loss of <i>LDAH</i> associated with prostate cancer and hearing loss. <i>Human Molecular Genetics</i> , 2018, 27, 4194-4203.	1.4	14
76	Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 341-348.	0.9	5
77	The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-“Clear Cell Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2018, 6, 758-765.	1.6	89
78	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. <i>Nature Genetics</i> , 2018, 50, 1271-1281.	9.4	438
79	Evaluation of predictive biomarkers for nivolumab in metastatic clear cell renal cell carcinoma (mccRCC) using RECIST and immune-related (IR) RECIST.. <i>Journal of Clinical Oncology</i> , 2018, 36, 619-619.	0.8	2
80	Genomic alterations to refine prognostication of patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 626-626.	0.8	1
81	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS710-TPS710.	0.8	1
82	Statin use and risk of renal cell carcinoma in three prospective cohort studies.. <i>Journal of Clinical Oncology</i> , 2018, 36, 679-679.	0.8	0
83	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4597-TPS4597.	0.8	0
84	Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. <i>Oncologist</i> , 2017, 22, 286-292.	1.9	54
85	Renal cell carcinoma. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17009.	18.1	1,727
86	Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. <i>Cancer Discovery</i> , 2017, 7, 750-765.	7.7	112
87	Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2017, 72, 557-564.	0.9	108
88	Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. <i>Journal of Urology</i> , 2017, 198, 817-823.	0.2	31
89	HIF activation causes synthetic lethality between the <i>VHL</i> tumor suppressor and the <i>EZH1</i> histone methyltransferase. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	36
90	In Reply. <i>Oncologist</i> , 2017, 22, 1561-1561.	1.9	0

#	ARTICLE	IF	CITATIONS
91	FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 2159-2168.	3.2	12
92	p63+ ureteric bud tip cells are progenitors of intercalated cells. <i>JCI Insight</i> , 2017, 2, .	2.3	14
93	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4573-4573.	0.8	1
94	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4596-TPS4596.	0.8	7
95	Impact of immune checkpoint protein expression in tumor cells and tumor infiltrating CD8 <sup>+</sup> T cells on clinical benefit from PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 477-477.	0.8	9
96	Genomic profiling of nephrectomy and metastatic sites in patients with advanced clear cell renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 513-513.	0.8	1
97	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression. <i>Oncotarget</i> , 2017, 8, 103428-103436.	0.8	19
98	Evolution of circulating tumor DNA (ctDNA) profile from first-line (1L) to second-line (2L) therapy in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 434-434.	0.8	2
99	The association of tumor infiltrating CD8 <sup>+</sup> and Foxp3 <sup>+</sup> cells with overall response rate (ORR) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose aldesleukin (HD IL-2).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4576-4576.	0.8	0
100	Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. <i>Oncotarget</i> , 2016, 7, 34341-34355.	0.8	258
101	Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development. <i>PLoS Genetics</i> , 2016, 12, e1006242.	1.5	93
102	Paracrine Induction of HIF by Glutamate in Breast Cancer: Egln1 Senses Cysteine. <i>Cell</i> , 2016, 166, 126-139.	13.5	187
103	A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. <i>Cancer</i> , 2016, 122, 2389-2398.	2.0	16
104	Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 304-313.e6.	0.9	11
105	Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma. <i>European Urology Focus</i> , 2016, 2, 633-639.	1.6	12
106	On-target efficacy of a HIF-2 $\beta$ antagonist in preclinical kidney cancer models. <i>Nature</i> , 2016, 539, 107-111.	13.7	341
107	Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. <i>Journal of Clinical Oncology</i> , 2016, 34, 3655-3663.	0.8	174
108	Killer immunoglobulin-like receptor (KIR) and KIR ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1523-1532.	2.0	5

#	ARTICLE	IF	CITATIONS
109	pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner. <i>Science</i> , 2016, 353, 929-932.	6.0	165
110	Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. <i>Scientific Reports</i> , 2016, 6, 27702.	1.6	46
111	Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 820-824.	2.3	36
112	Landscape of tumor-infiltrating T cell repertoire of human cancers. <i>Nature Genetics</i> , 2016, 48, 725-732.	9.4	288
113	Intratumor Heterogeneity of Perfusion and Diffusion in Clear-Cell Renal Cell Carcinoma: Correlation With Tumor Cellularity. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e585-e594.	0.9	31
114	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 2445-2452.	3.2	193
115	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016, 374, 135-145.	13.9	1,040
116	Tumor Vascularity in Renal Masses: Correlation of Arterial Spin-Labeled and Dynamic Contrast-Enhanced Magnetic Resonance Imaging Assessments. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e25-e36.	0.9	44
117	Association of higher PD-L1 expression in tumor cells of metastatic ccRCC lesions with worse overall survival.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23221-e23221.	0.8	1
118	Programmed death-ligand 1 (PD-L1) expression in cured and not cured testicular and other germ cell tumors (GCT).. <i>Journal of Clinical Oncology</i> , 2016, 34, 485-485.	0.8	1
119	T-cell receptor (TCR) repertoire in metastatic renal cell carcinoma (RCC) patients treated with first-line vascular endothelial growth factor receptor blockade.. <i>Journal of Clinical Oncology</i> , 2016, 34, 501-501.	0.8	1
120	Integrated genomic correlates of response to PD-1 inhibitor nivolumab in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 545-545.	0.8	9
121	Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation. <i>Oncotarget</i> , 2016, 7, 29901-29915.	0.8	47
122	The impact of PBRM1 and BAP1 expression on outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).. <i>Journal of Clinical Oncology</i> , 2016, 34, 616-616.	0.8	0
123	Differential expression of PD-L1 expression in high grade T1 (HGT1) v. muscle invasive urothelial carcinoma (MIUC) and its prognostic implications.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4535-4535.	0.8	0
124	Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. <i>Cancer</i> , 2015, 121, 3435-3443.	2.0	64
125	Immunohistochemical staining for BRAF V600E supports the diagnosis of metanephric adenoma. <i>Histopathology</i> , 2015, 66, 901-904.	1.6	23
126	Young investigator challenge: Application of cytologic techniques to circulating tumor cell specimens: Detecting activation of the oncogenic transcription factor STAT3. <i>Cancer Cytopathology</i> , 2015, 123, 696-706.	1.4	11



#	ARTICLE	IF	CITATIONS
127	Cell Kinetic Studies Fail to Identify Sequentially Proliferating Progenitors as the Major Source of Epithelial Renewal in the Adult Murine Prostate. PLoS ONE, 2015, 10, e0128489.	1.1	7
128	Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. , 2015, 3, 3.		76
129	Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Cancer Immunology Research, 2015, 3, 1158-1164.	1.6	237
130	PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. Cancer Immunology Research, 2015, 3, 1308-1315.	1.6	114
131	Suppression of <i>CHK1</i> by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis. Cancer Discovery, 2015, 5, 550-563.	7.7	24
132	RNA-seq Reveals Aurora Kinase-Driven mTOR Pathway Activation in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma. Molecular Cancer Research, 2015, 13, 130-137.	1.5	38
133	The High-Dose Aldesleukin Select-Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2015, 21, 561-568.	3.2	133
134	Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer. Clinical Cancer Research, 2015, 21, 1925-1934.	3.2	67
135	Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial. Clinical Cancer Research, 2015, 21, 1071-1077.	3.2	217
136	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discovery, 2015, 5, 1164-1177.	7.7	821
137	Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo. Molecular Cancer, 2015, 14, 119.	7.9	50
138	Adult Renal Cell Carcinoma. Surgical Pathology Clinics, 2015, 8, 587-621.	0.7	33
139	$\tilde{\gamma}$ Np63 (p40) expression in prostatic adenocarcinoma with diffuse p63 positivity. Human Pathology, 2015, 46, 384-389.	1.1	13
140	Activating genomic mutations in the mTOR pathway to predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort.. Journal of Clinical Oncology, 2015, 33, 4519-4519.	0.8	1
141	The impact of BMI on outcomes of patients with metastatic renal cell carcinoma treated with targeted therapy: An external validation data set and analysis of underlying biology from The Cancer Genome Atlas.. Journal of Clinical Oncology, 2015, 33, 405-405.	0.8	2
142	A phase II trial of sunitinib and gemcitabine in sarcomatoid and/or poor-risk patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 408-408.	0.8	2
143	Whole-exome sequencing (WES) predicting two extreme phenotypes of response to VEGF-targeted therapies (VEGF-TT) in patients with metastatic clear cell renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2015, 33, 422-422.	0.8	1
144	Prognostic value of genomic signatures in metastatic Clear Cell Renal Cell Carcinoma (mRCC) using The Cancer Genome Atlas (TCGA) data.. Journal of Clinical Oncology, 2015, 33, 4560-4560.	0.8	0

#	ARTICLE	IF	CITATIONS
145	Identification of ALK Gene Alterations in Urothelial Carcinoma. PLoS ONE, 2014, 9, e103325.	1.1	9
146	Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma. Cancer Discovery, 2014, 4, 1140-1153.	7.7	506
147	Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma. Clinical Cancer Research, 2014, 20, 1873-1883.	3.2	63
148	MET as a Target in Papillary Renal Cell Carcinoma. Clinical Cancer Research, 2014, 20, 3361-3363.	3.2	20
149	GRK3 is essential for metastatic cells and promotes prostate tumor progression. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1521-1526.	3.3	39
150	A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis. EMBO Molecular Medicine, 2014, 6, 519-538.	3.3	168
151	The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma. Cancer Cell, 2014, 26, 319-330.	7.7	665
152	Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor. Cancer Cell, 2014, 26, 222-234.	7.7	71
153	D-Cyclins Repress Apoptosis in Hematopoietic Cells by Controlling Death Receptor Fas and Its Ligand FasL. Developmental Cell, 2014, 30, 255-267.	3.1	27
154	Targeting Lactate Dehydrogenase-A Inhibits Tumorigenesis and Tumor Progression in Mouse Models of Lung Cancer and Impacts Tumor-Initiating Cells. Cell Metabolism, 2014, 19, 795-809.	7.2	411
155	Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib. Cancer Discovery, 2014, 4, 546-553.	7.7	266
156	Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates. Journal of Clinical Oncology, 2014, 32, 1889-1894.	0.8	229
157	Poor prognosis and advanced clinicopathological features of clear cell renal cell carcinoma (ccRCC) are associated with cytoplasmic subcellular localisation of Hypoxia inducible factor-2 $\alpha$ . European Journal of Cancer, 2014, 50, 1531-1540.	1.3	29
158	Vulnerabilities of PTEN <sup>-/-</sup> TP53 <sup>-/-</sup> -Deficient Prostate Cancers to Compound PARP <sup>-/-</sup> PI3K Inhibition. Cancer Discovery, 2014, 4, 896-904.	7.7	88
159	Depletion of a Putatively Druggable Class of Phosphatidylinositol Kinases Inhibits Growth of p53-Null Tumors. Cell, 2013, 155, 844-857.	13.5	173
160	Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncology, The, 2013, 14, 81-87.	5.1	52
161	SQSTM1 Is a Pathogenic Target of 5q Copy Number Gains in Kidney Cancer. Cancer Cell, 2013, 24, 738-750.	7.7	135
162	Renal-cell carcinoma: a step closer to a new classification. Lancet Oncology, The, 2013, 14, 105-107.	5.1	7

#	ARTICLE	IF	CITATIONS
163	Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1788-1793.	0.8	41
164	A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. <i>Nature Genetics</i> , 2013, 45, 747-755.	9.4	138
165	Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. <i>Nature Genetics</i> , 2013, 45, 739-746.	9.4	134
166	The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 5218-5226.	3.2	77
167	Opposing Effects of Androgen Deprivation and Targeted Therapy on Prostate Cancer Prevention. <i>Cancer Discovery</i> , 2013, 3, 44-51.	7.7	47
168	Animal Models of Human Prostate Cancer: The Consensus Report of the New York Meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. <i>Cancer Research</i> , 2013, 73, 2718-2736.	0.4	203
169	Identification of CDCP1 as a hypoxia-inducible factor 2 $\pm$ (HIF-2 $\pm$ ) target gene that is associated with survival in clear cell renal cell carcinoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 3483-3488.	3.3	57
170	p63-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 8105-8110.	3.3	185
171	Inhibition of tumor growth in a VEGFR TKI-resistant model of renal cell carcinoma using dalantercept combined with sunitinib. <i>Journal of Clinical Oncology</i> , 2013, 31, 370-370.	0.8	1
172	Relationship of ERCC1 genotype variant with mRNA expression and ERCC1 protein levels in advanced urothelial carcinoma (UC). <i>Journal of Clinical Oncology</i> , 2013, 31, 260-260.	0.8	0
173	A phase II multicenter study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy with pegfilgrastim support in patients (pts) muscle-invasive urothelial cancer (MIUC): Safety, pathologic, radiologic, and molecular correlates. <i>Journal of Clinical Oncology</i> , 2013, 31, 278-278.	0.8	0
174	Investigating the association of cytoplasmic and nuclear HIF-2 expression with cancer specific survival (CSS) in clear cell renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 387-387.	0.8	0
175	The Requirement for Cyclin D Function in Tumor Maintenance. <i>Cancer Cell</i> , 2012, 22, 438-451.	7.7	284
176	BRAF Mutations in Metanephric Adenoma of the Kidney. <i>European Urology</i> , 2012, 62, 917-922.	0.9	95
177	RET protein expression in papillary renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 900-905.	0.8	14
178	The Glomovenous Malformation Protein Glomulin Binds Rbx1 and Regulates Cullin RING Ligase-Mediated Turnover of Fbw7. <i>Molecular Cell</i> , 2012, 46, 67-78.	4.5	59
179	Identification of Luminal Breast Cancers That Establish a Tumor-Supportive Macroenvironment Defined by Proangiogenic Platelets and Bone Marrow-Derived Cells. <i>Cancer Discovery</i> , 2012, 2, 1150-1165.	7.7	142
180	Tissue Biomarkers in Renal Cell Carcinoma: Intermediate Endpoints in the Selection of Targeted Agents for RCC. , 2012, , 69-89.		0

#	ARTICLE	IF	CITATIONS
181	Radiofrequency ablation combined with liposomal quercetin to increase tumour destruction by modulation of heat shock protein production in a small animal model. <i>International Journal of Hyperthermia</i> , 2011, 27, 527-538.	1.1	49
182	Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. <i>Nature Genetics</i> , 2011, 43, 964-968.	9.4	270
183	Genetic and Functional Studies Implicate <i>HIF1<math>\alpha</math></i> as a 14q Kidney Cancer Suppressor Gene. <i>Cancer Discovery</i> , 2011, 1, 222-235.	7.7	347
184	Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression. <i>PLoS ONE</i> , 2011, 6, e19144.	1.1	64
185	SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. <i>Nature</i> , 2011, 470, 269-273.	13.7	462
186	Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients. <i>Journal of Pathology</i> , 2011, 225, 212-221.	2.1	35
187	Pml represses tumour progression through inhibition of mTOR. <i>EMBO Molecular Medicine</i> , 2011, 3, 249-257.	3.3	18
188	Transgenic Expression of Polyomavirus Middle T Antigen in the Mouse Prostate Gives Rise to Carcinoma. <i>Journal of Virology</i> , 2011, 85, 5581-5592.	1.5	5
189	Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking <i>Rb1</i> or <i>Men1</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 13379-13386.	3.3	143
190	FoxOs Enforce a Progression Checkpoint to Constrain mTORC1-Activated Renal Tumorigenesis. <i>Cancer Cell</i> , 2010, 18, 472-484.	7.7	127
191	The landscape of somatic copy-number alteration across human cancers. <i>Nature</i> , 2010, 463, 899-905.	13.7	3,331
192	Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. <i>BJU International</i> , 2010, 106, 772-778.	1.3	81
193	The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BE235 Compared with Rapamycin in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2010, 16, 3628-3638.	3.2	180
194	Loss of Hypoxia-Inducible Factor Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic Cardiomyopathy. <i>Circulation</i> , 2010, 122, 1004-1016.	1.6	139
195	Carbonic Anhydrase IX Expression in Renal Neoplasms. <i>American Journal of Clinical Pathology</i> , 2010, 134, 873-879.	0.4	97
196	Renal Cancer Resistance to Antiangiogenic Therapy Is Delayed by Restoration of Angiostatic Signaling. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2793-2802.	1.9	63
197	Liposomal Doxorubicin Increases Radiofrequency Ablation-induced Tumor Destruction by Increasing Cellular Oxidative and Nitritive Stress and Accelerating Apoptotic Pathways. <i>Radiology</i> , 2010, 255, 62-74.	3.6	75
198	Do Liposomal Apoptotic Enhancers Increase Tumor Coagulation and End-Point Survival in Percutaneous Radiofrequency Ablation of Tumors in a Rat Tumor Model?. <i>Radiology</i> , 2010, 257, 685-696.	3.6	49

#	ARTICLE	IF	CITATIONS
199	A constitutively activated form of the p110 <sup>β</sup> isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 11002-11007.	3.3	57
200	LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 626-635.	1.9	208
201	Fatty Acid Synthase: A Metabolic Enzyme and Candidate Oncogene in Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2009, 101, 519-532.	3.0	328
202	Patterns of Gene Expression and Copy-Number Alterations in von-Hippel Lindau Disease-Associated and Sporadic Clear Cell Carcinoma of the Kidney. <i>Cancer Research</i> , 2009, 69, 4674-4681.	0.4	370
203	Does Arterial Spin-labeling MR Imaging “measured Tumor Perfusion Correlate with Renal Cell Cancer Response to Antiangiogenic Therapy in a Mouse Model?”. <i>Radiology</i> , 2009, 251, 731-742.	3.6	111
204	Reciprocal Effects of STAT5 and STAT3 in Breast Cancer. <i>Molecular Cancer Research</i> , 2009, 7, 966-976.	1.5	121
205	Risk of Bilateral Renal Cell Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 3737-3741.	0.8	42
206	Treatment selection for patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2009, 115, 2327-2333.	2.0	32
207	Tissue biomarkers in renal cell carcinoma: Issues and solutions. <i>Cancer</i> , 2009, 115, 2290-2297.	2.0	36
208	Blood Levels of Carbonic Anhydrase 9 Correlate with Clear Cell Renal Cell Carcinoma Activity. <i>Clinical Proteomics</i> , 2009, 5, 37-45.	1.1	6
209	p63 Promotes Cell Survival through Fatty Acid Synthase. <i>PLoS ONE</i> , 2009, 4, e5877.	1.1	29
210	Adult Prostate Epithelium Renewal, Stem Cells and Cancer. , 2009, , 231-246.		0
211	p63 in prostate biology and pathology. <i>Journal of Cellular Biochemistry</i> , 2008, 103, 1354-1368.	1.2	72
212	Essential roles of PI(3)K p110 <sup>β</sup> in cell growth, metabolism and tumorigenesis. <i>Nature</i> , 2008, 454, 776-779.	13.7	654
213	VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. <i>Nature Cell Biology</i> , 2008, 10, 361-369.	4.6	216
214	Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy. <i>BJU International</i> , 2008, 101, 31-35.	1.3	12
215	A Prostatic Intraepithelial Neoplasia-Dependent p27Kip1 Checkpoint Induces Senescence and Inhibits Cell Proliferation and Cancer Progression. <i>Cancer Cell</i> , 2008, 14, 146-155.	7.7	153
216	Perfusion MDCT Enables Early Detection of Therapeutic Response to Antiangiogenic Therapy. <i>American Journal of Roentgenology</i> , 2008, 191, 133-139.	1.0	67

#	ARTICLE	IF	CITATIONS
217	Tissue-Based Research in Kidney Cancer: Current Challenges and Future Directions. <i>Clinical Cancer Research</i> , 2008, 14, 3699-3705.	3.2	24
218	Combination of Radiofrequency Ablation with Antiangiogenic Therapy for Tumor Ablation Efficacy: Study in Mice. <i>Radiology</i> , 2007, 244, 464-470.	3.6	75
219	The Role of Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 758s-763s.	3.2	91
220	Potential Histologic and Molecular Predictors of Response to Temsirolimus in Patients with Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2007, 5, 379-385.	0.9	168
221	High-throughput oncogene mutation profiling in human cancer. <i>Nature Genetics</i> , 2007, 39, 347-351.	9.4	927
222	Cytokeratin15-Positive Basal Epithelial Cells Targeted in Graft-Versus-Host Disease Express a Constitutive Antiapoptotic Phenotype. <i>Journal of Investigative Dermatology</i> , 2007, 127, 106-115.	0.3	26
223	Prostate stem cells: From development to cancer. <i>Seminars in Cancer Biology</i> , 2007, 17, 219-224.	4.3	35
224	A Working Group Classification of Focal Prostate Atrophy Lesions. <i>American Journal of Surgical Pathology</i> , 2006, 30, 1281-1291.	2.1	123
225	Improved Tumor Destruction with Arsenic Trioxide and Radiofrequency Ablation in Three Animal Models. <i>Radiology</i> , 2006, 240, 82-89.	3.6	47
226	Androgen-Dependent Regulation of Her-2/neu in Prostate Cancer Cells. <i>Cancer Research</i> , 2006, 66, 5723-5728.	0.4	71
227	Defining Cell Lineages in the Prostate Epithelium. <i>Cell Cycle</i> , 2006, 5, 138-141.	1.3	42
228	Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 3714-3721.	3.2	401
229	Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN <sup>+/-</sup> mice by the p85 regulatory subunits of phosphoinositide 3-kinase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 10238-10243.	3.3	43
230	Combination Radiofrequency Ablation with Intratumoral Liposomal Doxorubicin: Effect on Drug Accumulation and Coagulation in Multiple Tissues and Tumor Types in Animals. <i>Radiology</i> , 2005, 235, 469-477.	3.6	84
231	p63 regulates commitment to the prostate cell lineage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 11355-11360.	3.3	134
232	Reduced Tumor Growth with Combined Radiofrequency Ablation and Radiation Therapy in a Rat Breast Tumor Model. <i>Radiology</i> , 2005, 235, 81-88.	3.6	60
233	Arginase-Producing Myeloid Suppressor Cells in Renal Cell Carcinoma Patients: A Mechanism of Tumor Evasion. <i>Cancer Research</i> , 2005, 65, 3044-3048.	0.4	750
234	Androgen-Induced Differentiation and Tumorigenicity of Human Prostate Epithelial Cells. <i>Cancer Research</i> , 2004, 64, 8867-8875.	0.4	170

#	ARTICLE	IF	CITATIONS
235	Hypoxia regulation of the cell cycle in malignant melanoma: putative role for the cyclin-dependent kinase inhibitor p27Kip1. <i>Journal of Cutaneous Pathology</i> , 2004, 31, 477-482.	0.7	18
236	The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. <i>Cancer Cell</i> , 2004, 5, 253-261.	7.7	304
237	Intermediate basal cells of the prostate: In vitro and in vivo characterization. <i>Prostate</i> , 2003, 55, 206-218.	1.2	97
238	Diagnostic Utility of Immunohistochemical Staining for p63, a Sensitive Marker of Prostatic Basal Cells. <i>Modern Pathology</i> , 2002, 15, 1302-1308.	2.9	116
239	Obligate Roles for p16 Ink4a and p19 Arf -p53 in the Suppression of Murine Pancreatic Neoplasia. <i>Molecular and Cellular Biology</i> , 2002, 22, 635-643.	1.1	68
240	Gene Transcript Quantitation by Real-Time RT-PCR in Cells Selected by Immunohistochemistry-Laser Capture Microdissection. <i>Diagnostic Molecular Pathology</i> , 2002, 11, 187-192.	2.1	22
241	Stabilization of $\beta$ -catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia. <i>Oncogene</i> , 2002, 21, 4099-4107.	2.6	102
242	Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. <i>Nature</i> , 2002, 419, 162-167.	13.7	390
243	Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. <i>Journal of Clinical Investigation</i> , 2002, 110, 633-641.	3.9	142
244	Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. <i>Cancer Research</i> , 2002, 62, 89-98.	0.4	97
245	Estrogen Receptor $\beta$ in Prostate Cancer. <i>American Journal of Pathology</i> , 2001, 159, 13-16.	1.9	72
246	Primary effusion lymphoma in HIV-infected patients with multicentric Castleman's disease. <i>Journal of Pathology</i> , 2001, 193, 200-209.	2.1	47
247	Androgen-Driven Prostate Epithelial Cell Proliferation and Differentiation in Vivo Involve the Regulation of p27. <i>Molecular Endocrinology</i> , 2001, 15, 765-782.	3.7	77
248	Transition from In Situ to Invasive Testicular Germ Cell Neoplasia is Associated with the Loss of p21 and Gain of mdm-2 Expression. <i>Modern Pathology</i> , 2001, 14, 437-442.	2.9	57
249	Primary effusion lymphoma in HIV-infected patients with multicentric Castleman's disease. <i>Journal of Pathology</i> , 2001, 193, 200-209.	2.1	4
250	Detection of TCR- $\beta$ gene rearrangements in early mycosis fungoides by non-radioactive PCR-SSCP. <i>Journal of Cutaneous Pathology</i> , 2000, 27, 228-234.	0.7	47
251	Forkhead Transcription Factors Are Critical Effectors of Cell Death and Cell Cycle Arrest Downstream of PTEN. <i>Molecular and Cellular Biology</i> , 2000, 20, 8969-8982.	1.1	530
252	BCR/ABL Regulates Expression of the Cyclin-dependent Kinase Inhibitor p27Kip1 through the Phosphatidylinositol 3-Kinase/AKT Pathway. <i>Journal of Biological Chemistry</i> , 2000, 275, 39223-39230.	1.6	188

#	ARTICLE	IF	CITATIONS
253	p63 Is a Prostate Basal Cell Marker and Is Required for Prostate Development. American Journal of Pathology, 2000, 157, 1769-1775.	1.9	538
254	Role of the Cdc25A phosphatase in human breast cancer. Journal of Clinical Investigation, 2000, 106, 753-761.	3.9	186
255	Detection of Clonal T-Cell Receptor $\beta$ Gene Rearrangements in Paraffin-Embedded Tissue by Polymerase Chain Reaction and Nonradioactive Single-Strand Conformational Polymorphism Analysis. American Journal of Pathology, 1999, 154, 67-75.	1.9	79
256	Melanocytic Nevi of Palms and Soles. American Journal of Surgical Pathology, 1999, 23, 283-287.	2.1	54
257	Primary Cutaneous Marginal Zone B-Cell Lymphoma: A Recently Described Entity of Low-Grade Malignant Cutaneous B-Cell Lymphoma. American Journal of Surgical Pathology, 1997, 21, 1307-1315.	2.1	249
258	Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma. Oncotarget, 0, 7, 41857-41869.	0.8	21